Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment
US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...
LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline
LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...
Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device
Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...
Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion
Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...
China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets
The Ministry of Industry and Information Technology (MIIT) has released a report on the first...
China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results
The National Health Commission (NHC) of China has released a notice detailing the results of...
EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi
Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...
Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement
Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment...
Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...
AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...
3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...
CStone Pharmaceuticals’ Sugemalimab Wins EU Nod as First-Line NSCLC Treatment
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has received marketing approval...
Alphamab’s KN057 Earns FDA Orphan Drug Designation for Hemophilia B Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has received another orphan drug...
Junshi Biosciences’ Toripalimab Recommended for EU Approval for Two Indications
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has been recommended for approval by...
Akeso Biopharma’s Ivonescimab NDA Accepted by NMPA, Strengthening NSCLC Treatment Options
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has received a significant boost...
Beijing Balance Medical Secures NMPA Nod for Pioneering Heart Valve Patch
Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology firm based in...
Hengrui Pharmaceuticals Advances in Breast Cancer Treatment with NMPA Clinical Trial Greenlight
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received...
MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology...
Zhejiang Haichang Biotech Secures EU Approval for Apexelsin: A New Hope in Cancer Treatment
Zhejiang Haichang Biotech Co., Ltd, a partner of China-based Kexing Pharmaceutical (SHA: 688136), has secured...